Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (21)

2024

  1. Oculomotor Dysfunction in Idiopathic and LRRK2-Parkinson's Disease and At-Risk Individuals

    Journal of Parkinson's disease, Vol. 14, Núm. 4, pp. 797-808

2023

  1. Analysis of retinal nerve layers in idiopathic, LRRK2-associated Parkinson's disease and unaffected carriers of G2019S mutation

    Parkinsonism and Related Disorders, Vol. 106

  2. Differential serum microRNAs in premotor LRRK2 G2019S carriers from Parkinson’s disease

    npj Parkinson's Disease, Vol. 9, Núm. 1

2022

  1. Sensor-based gait analysis in the premotor stage of LRRK2 G2019S-associated Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 98, pp. 21-26

2021

  1. Finding genetically-supported drug targets for Parkinson’s disease using Mendelian randomization of the druggable genome

    Nature Communications, Vol. 12, Núm. 1

  2. Serial DaT-SPECT imaging in asymptomatic carriers of LRRK2 G2019S mutation: 8 years’ follow-up

    European Journal of Neurology, Vol. 28, Núm. 12, pp. 4204-4208

2020

  1. Regulatory sites for splicing in human basal ganglia are enriched for disease-relevant information

    Nature Communications, Vol. 11, Núm. 1

2019

  1. Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset

    npj Parkinson's Disease, Vol. 5, Núm. 1

  2. Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability

    npj Parkinson's Disease, Vol. 5, Núm. 1

  3. The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight

    Movement Disorders, Vol. 34, Núm. 12, pp. 1851-1863

2018

  1. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain

    Movement Disorders, Vol. 33, Núm. 4, pp. 637-641

2016

  1. COPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global -clinical evaluations, serum biomarkers, genetic studies and neuroimaging- prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression

    BMC Neurology, Vol. 16, Núm. 1

  2. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease

    Neurobiology of Aging, Vol. 38, pp. 214.e1-214.e5

2015

  1. Identification of candidate genes for Parkinson's disease through blood transcriptome analysis in LRRK2-G2019S carriers, idiopathic cases, and controls

    Neurobiology of Aging, Vol. 36, Núm. 2, pp. 1105-1109

2014

  1. Nonmotor symptoms in LRRK2 G2019S associated Parkinson's disease

    PLoS ONE, Vol. 9, Núm. 10

  2. Serum uric acid and risk of dementia in Parkinson's disease

    Parkinsonism and Related Disorders, Vol. 20, Núm. 6, pp. 637-639

2013

  1. Genetic variability related to serum uric acid concentration and risk of Parkinson's disease

    Movement Disorders, Vol. 28, Núm. 12, pp. 1737-1740

2012

  1. Common variation in the LRRK2 gene is a risk factor for Parkinson's disease

    Movement Disorders, Vol. 27, Núm. 14, pp. 1823-1826

2011

  1. Aspectos controvertidos en el manejo de gliomas hemisféricos OMS grado II: Revisión de la bibliografía reciente

    Revista de Neurologia, Vol. 53, Núm. 12, pp. 747-757

  2. High frequency and reduced penetrance of lRRK2 g2019S mutation among Parkinson's disease patients in Cantabria (Spain)

    Movement Disorders, Vol. 26, Núm. 13, pp. 2343-2346